Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 11, 1999, Pages 2638-2651

  Fortune, Brad ^a,b   Schneck, Marilyn E ^a   Adams, Anthony J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEVERS EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; EYE FUNDUS; FEMALE; HUMAN; MALE; NERVE CONDUCTION; PRIORITY JOURNAL; RETINA DEGENERATION;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEMALE; FUNDUS OCULI; HUMANS; MALE; MIDDLE AGED; RETINA; SENSITIVITY AND SPECIFICITY;

EID: 0032833358     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Yonemura D, Aoki T, Tsuzuki K. Electroretinogram in diabetic retinopathy. Arch Ophthalmol. 1962;68:19-24.
2. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retinal Eye Res. 1998;17:59-76.
3. Coupland SG. A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol. 1987;66:207-218.
4. Simonsen SE. The value of the oscillatory potentials in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol. 1980;58:865-878.
5. Bresnick GH, Palta M. Predicting progression to severe proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105:929-933.
6. Bresnick GH, Palta M. Temporal aspects of the electroretinogram in diabetic retinopathy. Arch Ophthalmol. 1987;105:660-664.
7. Satoh S, Iijima H, Imai M, Abe K, Shibuya T. Photopic electroretinogram implicit time in diabetic retinopathy. Jpn J Ophthalmol. 1994;38:178-184.
8. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1992;33:2773-2780.
9. Xu X, Karwoski CJ. Current source density analysis of retinal field potentials, II: pharmacological analysis of the b-wave and m-wave. J Neurophysiol. 1994;72:96-105.
10. Xu X, Karwoski CJ. Current source density analysis of the electroretinographic d-wave of frog retina. J Neurophysiol. 1995;73: 2459-2469.
11. Bush RA, Sieving PA. A proximal retinal component in the primate photopic ERG a-wave. Invest Ophthalmol Vis Sci. 1994;35:635-645.
12. Bush RA, Sieving PA. Inner retinal contributions to the primate photopic fast flicker electroretinogram. J Opt Soc Am A. 1996;13: 557-565.
13. Sieving PA, Murayama K, Naarendorp F. Push-pull model of the primate photopic electroretinogram: a role for hyperpolarizing neurons in shaping the b-wave. Vis Neurosci. 1994;11:519-32.
14. Hood DC, Birch DG. b Wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. J Opt Soc Am A. 1996;13:1-11.
15. Hood DC, Birch DG. Human cone receptor activity: the leading edge of the a-wave and models of receptor activity. Vis Neurosci. 1993;10:857-871.
16. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE. Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:2355-2365.
17. Birch DG. Focal electroretinography. In: Heckenlively JR, Arden GB, eds. Principles and Practice of Clinical Electrophysiology of Vision, St. Louis: Mosby; 1991:334-338.
18. Bresnick GH. Nonproliferative diabetic retinopathy. In: Ryan SJ, ed. Retina. Vol. 2. St. Louis: Mosby; 1994:1277-1318.
19. Di Leo MA, Caputo S, Falsini B, Porciatti V, Greco AV, Ghirlanda G. Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy. Diabetologia. 1994;37:911-916.
20. Biersdorf WR. The clinical utility of the foveal electroretinogram: a review. Doc Ophthalmol. 1989;73:313-325.
21. Sutter EE, Tran D. The field topography of ERG components in man, I: the photopic luminance response. Vision Res. 1992;32: 433-446.
22. Bearse MA, Sutter EE. Imaging localized retinal dysfunction with the multifocal electroretinogram. J Opt Soc Am A. 1996;13:634-640.
23. Hood DC, Holopigian K, Greenstein V, et al. Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique. Vision Res. 1998;38:163-179.
24. Seeliger MW, Kretschmann UH, Rüther KW, Apfelstedt-Sylla E, Zrenner E. Multifocal electroretinography in retinitis pigmentosa. Am J Ophthalmol. 1998;125:214-226.
25. Seeliger MW, Kretschmann UH, Apfelstedt-Sylla E, Zrenner E. Implicit time topography of multifocal electroretinograms. Invest Ophthalmol Vis Sci. 1998;39:718-723.
26. Bearse MA, Sutter EE, Sim D, Stamper R. Glaucomatous dysfunction revealed in higher order components of the electroretinogram. Vision Science and Its Applications. Technical Digest Series. Vol. 1, Washington, DC: Optical Society of America. 1996: 104-107.
27. Palmowski AM, Sutter EE, Bearse MA, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci. 1997;38:2586-2596.
28. Greenstein V, Holopigian K, Seiple W, Hood DC, Carr RE. The effects of focal laser treatment on multi-focal ERGs and visual fields in diabetic patients with macular edema. [ARVO abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S821. Abstract nr 3802.
29. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: report number 12. Ophthalmology. 1991;98: 823-833.
30. Hood DC, Li J. A technique for measuring individual multifocal ERG records. In: Yager D, ed. Non-invasive assessment of the visual system, Trends in Optics and Photonics. Vol. 11, Washington, DC: Optical Society of America; 1997:280-283.
31. Hood DC, Seiple W, Holopigian K, Greenstein V. A comparison of the components of the multifocal and full-field ERGs. Vis Neurosci. 1997;14:533-544.
32. Diabetic Retinopathy Study (DRS) Research Group, II: a modification of the Airlee House classification of diabetic retinopathy: DRS report number 7. Invest Ophthalmol Vis Sci. 1981;21:210-226.
33. Verdon WA, Haegerstrom-Portnoy G. Topography of the multifocal electroretinogram. Doc Ophthalmol. 1998;95:73-90.
34. Brown B, Yap MKH. Contrast and luminance as parameters defining the output of the VERIS topographical ERG. Ophthalmol Physiol Opt. 1996;16:42-48.
35. Bearse MA, Sutter EE. Contrast dependence of multifocal ERG components. Vision Science and Its Applications. Technical Digest Series. Vol. 1, Washington, DC: Optical Society of America. 1998:24-27.
36. Cao J, McLeod DS, Merges CA, Lutty GA. Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol. 1998;116:589-597.
37. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci. 1998;39:1647-1657.
38. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996;37:1334-1340.
39. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
40. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol. 1997;273:H2224-H2231.
41. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 1997;26:1497-1503.
42. Sone H, Kawakami Y, Okuda Y, Kondo S, et al. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem Biophys Res Commun. 1996;221:193-198.
43. Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:2729-2741.
44. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
45. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
46. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40: 726-730.
47. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998;47:401-406.
48. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
49. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.